⭐️Such a delight to meet the one & only Rishi Sunak @RishiSunak former UK Prime Minister. ⭐️Impressive presence, great clarity, infectious energy. Wow! Feeling grateful & energized & THANK YOU for your commitment to push for prostate cancer screening & research @PCFnews @ProstateUK @oncodaily @oncodaily @ASCO @myESMO @Aiims1742 @NCIDirector

⭐️Such a delight to meet the one & only Rishi Sunak @RishiSunak former UK Prime Minister. ⭐️Impressive presence, great clarity, infectious energy. Wow! Feeling grateful & energized & THANK YOU for your commitment to push for prostate cancer screening & research @PCFnews @ProstateUK @oncodaily @oncodaily @ASCO @myESMO @Aiims1742 @NCIDirector

🚨Another big win for #precisionmedicine 🚨👉🏼Today the FDA approved lirafugratinib for FGFR2‑rearranged cholangiocarcinoma. ⭐️I still remember the first patient in the universe we enrolled on the trial during the peak of the pandemic. Three days in - I called the amazing Ben- the then CMO of @Relay_Tx “Your drug is working, working too good. We need to work on the right dosing & get it right for patients. I think this baby will graduate someday.” That day is today 🙌🏼 Thankful to all patients who volunteered & the amazing teams that got this to finish line 🙏🏽 !!! @OncoAlert @oncodaily @OncBrothers @ElizSMcKenna @matthewherper @curecc @Aiims1742 @MiteshBorad @AliSchram 👉🏼Link to FDA approval fda.gov/drugs/resources-info… 👉🏼Link to @CD_AACR @AACR bench to bedside publication aacrjournals.org/cancerdisco…

The @US_FDA approved the FGFR2 inhibitor lirafugratinib for previously treated, advanced cholangiocarcinomas that cannot be surgically resected and that harbor certain alterations involving the FGFR2 gene: brnw.ch/21x5UNA

🚨Another big win for #precisionmedicine 🚨👉🏼Today the FDA approved lirafugratinib for FGFR2‑rearranged cholangiocarcinoma. ⭐️I still remember the first patient in the universe we enrolled on the trial during the peak of the pandemic. Three days in - I called the amazing Ben- the then CMO of @Relay_Tx “Your drug is working, working too good. We need to work on the right dosing & get it right for patients. I think this baby will graduate someday.” That day is today 🙌🏼 Thankful to all patients who volunteered & the amazing teams that got this to finish line 🙏🏽 !!! @OncoAlert @oncodaily @OncBrothers @ElizSMcKenna @matthewherper @curecc @Aiims1742 @MiteshBorad @AliSchram 👉🏼Link to FDA approval fda.gov/drugs/resources-info… 👉🏼Link to @CD_AACR @AACR bench to bedside publication aacrjournals.org/cancerdisco…

📣Super thrilled to share our paper on RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations & Resistance Mutations, published in @CD_AACR ! 👉🏼Huge thanks to team at Cancer Discovery & @AACR for making the front page & the entire paper so visually appealing  👏🏼#PrecisionMedicine 🧬🎯#cancerresearch @OncoAlert @ElizSMcKenna @Relay_Tx @TaliLev123 👉🏼Free Link: tinyurl.com/yfffae53

Together with Stephen Fry, Colin McFarlane, David Cameron, Steve McQueen, Jeremy Clarkson and Nick Jones, I’ve written to the Health Secretary about prostate cancer. Prostate cancer is now the most common cancer among men in Britain. It kills one man every 45 minutes, many after a diagnosis too late for treatment to succeed. Black men face a 1 in 4 lifetime risk, double that of the general population, and men whose fathers or brothers have had the disease face a similar threat. In May the National Screening Committee refused to extend screening beyond a group of just 1,500 men with one specific genetic variant. Everyone else at high risk doesn't have guaranteed access to a test that could save their life. We believe that's wrong, and that the Secretary of State has both the evidence and the power to overturn the ruling. More than 250 MPs from across the political spectrum have called for a targeted national screening programme, and over 100,000 people have signed petition demanding the same. A programme targeted at those at highest risk would cost £25 million a year, which is 0.01% of the NHS budget. We are asking the Secretary of State to reconsider the Committee's recommendation and commit to a targeted national screening programme; to act now, rather than wait a decade for further trial data while men continue to die; and to ensure that risk, not luck, decides who is tested.

3/8 Here's why rare cancers outperform: they often exhibit striking molecular homogeneity. BRAF V600E in ~95-100% of hairy cell leukemia. BCR::ABL defining CML. ETV6::NTRK3 in infantile fibrosarcoma. Simple biology = ideal precision medicine targets #PrecisionOncology @Dr_R_Kurzrock wrote about this in 2007 pubmed.ncbi.nlm.nih.gov/1743… This paper comments on @EytanRuppin 's paper in @myESMO Rare Cancers esmorarecancers.org/article/…

Today at 12pm, we are pleased to welcome Dr. Anirban Maitra @Aiims1742 for our #GrandRounds and Koenigsberg Lecture! Dr. Maitra will present "Mediators of Restraint in Early Pancreatic Neoplasia." Join us in Smilow Auditorium or online via Zoom: bit.ly/4gWZv7G. @SmilowCancer @Perlmutter_CC